Pulmatrix Enters Cross License Agreement With MannKind To Use Cricket Inhalation Device For Delivery Of PUR3100 And Other Dry Powder Formulations For Neurological Diseases
Portfolio Pulse from Benzinga Newsdesk
Pulmatrix has entered a cross-license agreement with MannKind to use the Cricket inhalation device for the delivery of PUR3100 and other dry powder formulations for neurological diseases.
May 29, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MannKind's cross-license agreement with Pulmatrix to use the Cricket inhalation device for neurological disease treatments could expand the device's applications and market reach.
The agreement with Pulmatrix could open new markets for MannKind's Cricket inhalation device, enhancing its application in the treatment of neurological diseases.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pulmatrix's new agreement with MannKind to use the Cricket inhalation device for delivering PUR3100 and other formulations could enhance its product offerings in the neurological disease space.
The partnership with MannKind allows Pulmatrix to leverage an established inhalation device, potentially accelerating the development and market entry of its neurological disease treatments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100